LOGIN  |  REGISTER
C4 Therapeutics

Merrimack Pharmaceuticals (NASDAQ: MACK) Stock Quote

Last Trade: US$14.77 0.02 0.14
Volume: 404,061
5-Day Change: 0.54%
YTD Change: 10.14%
Market Cap: US$214.610M

Latest News From Merrimack Pharmaceuticals

Special Meeting of Stockholders to Approve Plan of Dissolution Scheduled for Friday, May 10, 2024 at 10:00 a.m. Eastern Standard Time CAMBRIDGE, Mass. / Mar 27, 2024 / Business Wire / Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced that it has received a $225 million payment which was due from Ipsen, S.A. as a result of its receipt of approval from the U.S. Food and Drug... Read More
CAMBRIDGE, Mass. / Mar 07, 2024 / Business Wire / Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2023 financial results for the period ended December 31, 2023. “As Ipsen reported in February, the U.S. Food and Drug Administration has approved the supplemental new drug application for Onivyde® (irinotecan liposome injection) plus 5 fluorouracil/leucovorin and... Read More
FDA Approval Triggers $225 Million Milestone Payment from Ipsen to Merrimack Merrimack Expects to Hold Special Meeting of Stockholders to Approve Plan of Dissolution in May 2024 Following Approval of Plan of Dissolution, Merrimack Expects to Issue a Liquidating Dividend Currently Estimated to be Between $14.65 and $15.35 per Share in the Late Spring or Early Summer CAMBRIDGE, Mass. / Feb 13, 2024 / Business Wire / Merrimack... Read More
CAMBRIDGE, Mass. / Nov 02, 2023 / Business Wire / Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its third quarter 2023 financial results for the period ended September 30, 2023. “During the third quarter we saw interest income on our cash and short term investments offset a significant portion of our operating expenses” said Gary Crocker, Chairman of Merrimack's Board of... Read More
CAMBRIDGE, Mass. / Aug 03, 2023 / Business Wire / Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its second quarter 2023 financial results for the period ended June 30, 2023. “We were excited to see the announcement from Ipsen that the U.S. Food and Drug Administration (FDA) had accepted its supplemental new drug application (sNDA) Onivyde® (irinotecan liposome injection) plus... Read More
CAMBRIDGE, Mass. / May 04, 2023 / Business Wire / Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2023 financial results for the period ended March 31, 2023. “During the first quarter of 2023 our operating expenses remained consistent with prior quarters and were reduced both by proceeds we received from the receipt of an option fee paid in connection with the... Read More
CAMBRIDGE, Mass. / Mar 09, 2023 / Business Wire / Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2022 financial results for the period ended December 31, 2022. “We are encouraged by the results of the NAPOLI 3 trial as reported by Ipsen in November 2022 and the guidance that Ipsen has subsequently provided regarding its intention to file a supplemental New Drug... Read More
Assertio

COPYRIGHT ©2023 HEALTH STOCKS HUB